 AMARILLO, TX ACCESSWIRE December 30, 2020 Amarillo Biosciences, Inc. we, ABI or the Company, OTC PINK:AMAR, a company engaged in low-dose non-injectable interferon research, announced today that it has entered into a Securities Purchase Agreement Agreement with a strategic investor, Ainos, Inc., a Cayman Islands corporation Ainos focused on advanced technology diagnostic medical devices and artificial intelligence consumer healthcare solutions. Ainos develops and manufactures point-of-care testing POCT rapid test kit products that include diagnostics for COVID-19 SARS CoV2 Antigen Rapid Test, pneumonia, vaginal infection, and helicobacter pylori H. 